Evaluating the Evidence: GLP1 Receptor Agonists Improve Cardiovascular Measures in Patients with Diabetes

TARGET AUDIENCE
The primary target audiences for the HCP activity are cardiologists and specialty NPs and PAs. The secondary target audiences are endocrinologists and primary care clinicians.

STATEMENT OF NEED/PROGRAM OVERVIEW
Of the 415 million people living with diabetes in the world, 90% have type 2 diabetes (T2D), which doubles the risk of major cardiovascular complications. Cardiovascular disease remains the major cause of increased mortality in this patient population.

Initially investigated as glucose-lowering therapies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have since demonstrated cardiac benefits and are becoming an important part of the cardiologist's armamentarium. Cardiologists are now faced with the challenge of identifying patients who best qualify for this therapeutic approach and selecting treatment in a patient-centric manner. However, a lack of familiarity with these agents may make cardiology clinicians hesitant to integrate these therapies into practice.

Join an esteemed panel of cardiology experts to evaluate the different GLP-1 RA formulations and explore how they differ in terms of documented cardiovascular impacts and weight reduction. Panelists will review the latest guideline recommendations on the management of CV risk in people with T2D and discuss the proper use of GLP-1 RAs in practice, including patient selection.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
• Differentiate the various GLP-1 RAs based on their documented impact on CV-related markers and weight reduction in addition to their glucose lowering properties
• Apply guideline-based recommendations regarding the use of GLP-1 RA therapy in patients with T2D